LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to outsmart HER2-Positive cancers
Disease control Recruiting nowThis early-stage study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and check for…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a combination of two drugs—trifluridine/tipiracil (a chemotherapy) and talazoparib (a targeted therapy)—in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side eff…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo targets Hard-to-Treat stomach cancer in early trial
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug IBI363 to standard chemotherapy can improve outcomes for people with a specific type of locally advanced stomach or gastroesophageal junction cancer (MHC-II-negative). The study will enroll 60 participants who will receive the…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a heart drug boost cancer treatment? new trial tests propranolol with chemo and immunotherapy
Disease control Recruiting nowThis phase 2 trial is testing whether adding propranolol, a common beta-blocker used for heart conditions, to standard chemotherapy and pembrolizumab (an immunotherapy) can improve treatment response in people with advanced esophageal or gastroesophageal junction cancer that cann…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC